Area of research
Oncology · Surgery
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Pancreatitis Pathology and Treatment, Cancer Genomics and Diagnostics, and Cholangiocarcinoma and Gallbladder Cancer Studies.
Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial
Photon and particle radiotherapy induce redundant modular chemotaxis of human lymphocytes
Multiscale and multimodal imaging for three-dimensional vascular and histomorphological organ structure analysis of the pancreas
DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’ experience of association studies to understand the genetic architecture of pancreatic cancer
Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system
Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin
Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer
Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma
Promoter Hypermethylation Promotes the Binding of Transcription Factor NFATc1, Triggering Oncogenic Gene Activation in Pancreatic Cancer
Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer
Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids
Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer
Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin
<i>SST</i> gene hypermethylation acts as a pan‐cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood‐based diagnosis
Genome‐wide association study identifies an early onset pancreatic cancer risk locus
The transcription factor FLI1 promotes cancer progression by affecting cell cycle regulation
Abstract C02: Establishment of a human PDAC explant culture model for treatment prediction and characterization of the tumor microenvironment
<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer
SLC22A3 polymorphisms may influence overall patient survival- PANDORA study
Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma
SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival
Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer
<i>HYAL2</i> methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study
Epithelial-specific E3 ligase CBLc regulates differentiation and motility of pancreatic cancer cells